BRCA2 and ovarian carcinoma: New findings that RAD52 is essential for cell viability in BRCA1-, PALB2- and BRCA2- and RAD51 paralog-deficient cells, but not in normal cells, suggested that RAD52 may represent an attractive therapeutic target for killing hereditary breast cancer and ovarian cancer cells.